Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
  • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
  • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
  • C07D241/54—Nitrogen atoms

Definitions

• the present invention relates to new amido-quinoxalinediones, processes for their preparation and their use for combating diseases.
• excitatory amino acids such as B. Glutamic acid are common in the central nervous system. These excitatory amino acids act as transmitter substances for the glutamate receptors, of which various subtypes are known.
• a subtype is e.g. B. named after the specific agonist N-methyl-E-aspartate NMDA receptor.
• This NMDA receptor has different binding sites for agonists or antagonists.
• the amino acid glycine also binds to the NMDA receptor and modulates the action of the natural agonist glutamic acid. Antagonists at this glycine binding site can then show antagonistic effects on the NMDA receptor and inhibit "overexcitation" of this receptor.
• AMPA 2-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
• kainic aeid Two other subtypes of the glutamate receptors are the AMPA and the kainate receptor, which are each named after the specific agonists 2-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainic aeid. Analogous to the NMDA receptor already mentioned, antagonists of these receptors could also inhibit "overexcitation”. A number of neurodegenerative diseases or mental disorders result in increased glutamate levels, which can lead to states of overexcitation or toxic effects in the CNS. Antagonists against the glutamate receptor subtypes can thus be used to treat these diseases.
• AMPA 2-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
• Glutamate antagonists including in particular NMDA antagonists or their modulators (such as glycine antagonists) and the AMPA antagonists, are therefore suitable for therapeutic use as agents against neurodegenerative diseases (Huutiustan chorea and Parkinson's diseases), neurotoxic disorders Hypoxia, anoxia or ischemia, as they occur after "Stroke”, or also as antiepileptics, antidepressants and anxiolytics (cf. pharmaceutical research 1990, 40, 511-514; TIPS, 1990, 11, 334-338 and drugs of the future 1989, 14 (11), 1059-1071).
• neurodegenerative diseases Huutiustan chorea and Parkinson's diseases
• Hypoxia Hypoxia
• anoxia or ischemia as they occur after "Stroke”
• anxiolytics cf. pharmaceutical research 1990, 40, 511-514; TIPS, 1990, 11, 334-338 and drugs of the future 1989, 14 (11), 1059-1071.
• R 1 in II represents a radical that is not hydrogen.
• R 1 in II represents a radical that is not hydrogen.
• EP 315,959, DE 4,135,871, WO 91 / 13,878, WO 92 / 07,847 and WO 94 / 00.124 describe alkyl radicals as R 1 in II, it being possible for the alkyl chain to be substituted with acids, esters or amides.
• the invention relates to new amidoquinoxalinediones
• R 1 is hydrogen or C 1 -C 4 alkyl, n is 0 or 1, m is 0, 1, 2, 3 or 4,
• R 2 is hydrogen, branched or rectilinear C 1 -C 6 alkyl or phenyl, which can be substituted with a maximum of two of the following radicals: rectilinear or branched C 1 -C 4 alkyl, OR 6 , NH 2 , NO 2 , NHCOR 6 , CN, CF 3 , OCF 3 , -CO 2 R 6 , F, Cl, Br, J, -CO-R 6 or SO 2 R 6 , wherein
• R 6 is hydrogen, C 1 -C 4 alkyl, phenyl or benzyl,
• R 3 is fluorine, chlorine, bromine, iodine, C 1 -C 4 alkyl, OR 7 , - CO-R 7 , NH 2 , NO 2 , -NH-CO-R 7 , CF 3 , CN or ', in which R 7 is hydrogen,
• Z 0 or NH and R 10 are hydrogen, straight or branched C 1 -C 4 alkyl, phenyl, benzyl, pyridyl or benzylhydryl, r 0, 1, 2, 3 or 4 and R 11 are hydrogen, straight or branched C 1 -C 4 alkyl, phenyl,
• R 9 is hydrogen or C 1 -C 4 alkyl and the benzene rings contained in R 8 , R 10 and R 11 are also replaced by one or two NH 2 , OCH 3 , OCH 2 CH 3 , Cl, Br, OCF 3 , F, CH 3 , C 2 H 5 , NO 2 , -COOR 1 , -CONHR 1 , -CH 2 NHR 1 , -CH 2 NH-CO-CF 3 , -CH 2 NH-CO-CH 3 , -NH -SO 2 -CH 3 , -NH-CO-CH 3 , -NH-CO-CF 3 and
• R 4 and R 5 which may be the same or different, and hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, trifluoromethyl, trifluoromethoxy, fluorine, bromine, iodine, nitro and cyano, and an anel - Liert benzene ring, which in turn can carry up to two of the radicals mentioned for R 4 and R 5 , mean and their tautomeric, isomeric and enantiomeric forms and their physiologically tolerable salts.
• R 1 is hydrogen or C 1 -C 4 alkyl, n is 0, m is 0, 1, 2, 3 or 4,
• R 1 is branched or straight-line C 1 -C 6 alkyl or phenyl, which can be substituted with a maximum of two of the following radicals: straight or branched C 1 -C 4 alkyl, OR 6 , NH 2 , NO 2 ,
• R 6 is hydrogen, C 1 -C 4 alkyl, phenyl or benzyl,
• R 3 is where q is the number 0, 1 or 2
• Z 0 or NH and R 10 are hydrogen, linear or branched C 1 -C 4 alkyl, phenyl, benzyl, pyridyl or benzylhydryl, r 0, 1, 2, 3 or 4 and R 11 are hydrogen, linear or branched C 1 -C 4 alkyl, phenyl, meaning
• R 8 , R 10 and R 11 can also be substituted by one or two of the following radicals: NH 2 , OCH 3 , OCH 2 CH 3 , Cl, Br, OCF 3 , F, CH 3 , C 2 H 5 , NO 2 , -COOR 1 , -CONHR 1 , -CH 2 NHR 1 , -CH 2 NH-CO-CF 3 , -CH 2 NH-CO-CH 5 , -NH-SO 2 -CH 3 , -NH-CO-CH 3 or -NH-CO-CF 3 and
• R 4 and R 5 which may be the same or different, are hydrogen, trifluoromethyl, nitro, cyano or a fused benzene ring.
• Amido-quinoxalinediones of the formula I are particularly preferred, wherein
• R 1 is hydrogen or C 1 - C 4 alkyl, n is 0, m is 0,
• R 2 is methyl or phenyl, which can be substituted by one or two straight-chain C 1 -C 4 -alkyl radicals,
• R 3 ' means where
• Z NH and R 10 are hydrogen, rectilinear or branched C 1 -C 2 alkyl, phenyl, benzyl, pyridyl or benzylhydryl, r 0, 1, 2, 3 or 4 and R 11 are hydrogen, rectilinear or branched C 1 -C 2 - Alkyl, phenyl or mean and
• R 8 , R 10 and R 11 may also be substituted by one or two of the following radicals: NH 2 , OCH 3 , OCH 2 CH 3 , Cl, Br, OCF 3 , F, CH 3 , C 2 H 5 , NO 2 ,
• Example 29 1,3-amido-7-pyrrolylquinoxalinedione
• 1-carbamoyl-7-pyrrolylquinoxalinedione cf. Example 56 in EP 572.852
• the 1-amido-quinoxalinediones according to the invention can be prepared in various ways.
• the group Z in IV stands for an amino protective group such as. B. trifluoroacetyl, acetyl, Boc and benzoyl.
• the conversion to V takes place in solvents, preferably polar solvents such as alcohols, acetonitrile, dimethylformamide and higher polyol derivatives, at temperatures of 25-150 ° C, preferably at 80-150 ° C, in the presence of a base such as tertiary amines and potassium carbonate.
• the derivative V gives activated oxalmono acids, such as. B. oxalic acid monoethyl chloride, the anilide derivatives VI.
• This amide formation is carried out by known methods in solvents such as tetrahydrofuran, methylene chloride, dimethylformamide or pyridine and, if appropriate, addition of bases such as triethylamine, pyridine, potassium carbonate or aqueous sodium hydroxide solution at temperatures of 0-30 ° C.
• bases such as triethylamine, pyridine, potassium carbonate or aqueous sodium hydroxide solution at temperatures of 0-30 ° C.
• the reduction of nitro-anilide VI to quinoxalinedione VII is achieved either catalytically or chemically.
• the catalytic reduction takes place in polar solvents, such as dimethylformamide, alcohols or tetrahydrofuran, in the presence of catalytic amounts of palladium / carbon, platinum / carbon or similar catalysts at temperatures of 25-100 ° C.
• polar solvents such as dimethylformamide, alcohols or tetrahydrofuran
• palladium / carbon platinum / carbon or similar catalysts at temperatures of 25-100 ° C.
• Hydrogen or hydrogen carrier such as
• Ammonium formate or hydrazine can be used.
• the chemical reduction is accomplished with metals such as iron and zinc or metal compounds such as tin-II-chloride in polar solvents such as water or glacial acetic acid, optionally with the addition of acids such as hydrochloric acid or acetic acid, at temperatures of 25-150 ° C, preferably 60-120 ° C.
• the protective group Z in VII is split off to the 1-aminoquinoxaline VIII, depending on the protective group, by known processes which are described in Th. Green et al., "Protective Groups in Organic Synthesis", Wiley & Sons 1991, chap. 7 are listed.
• the splitting off of the protective group Z to X and the introduction of the group X-CO- to the compounds Ib according to the invention is carried out analogously to the processes from scheme 1 (see above).
• the nitro-aromatic IX can be reduced to aniline X analogously to the reduction process from scheme 1 (step VI ⁇ VII).
• the aniline X is like a 1,4-dicarbonyl compound
• the substitution of the pyrrolyl ring claimed in R 7 can be changed in a suitable manner (Scheme 3).
• the aldehyde can be converted into the compounds I according to the invention by reductive amination with amines.
• the reductive amination is generally at temperatures of 5 to 80 ° C, preferably 10 to 30 ° C, in the presence of reducing agents such as sodium cyanoborohydride or hydrogen in the presence of hydrogenation catalysts such as Pd / carbon, Pt / carbon or Raney nickel, advantageously in polar organic solvents such as alcohols or dimethylformamide.
• the aldehyde Ic can by conventional methods such. B. in R.C. Larock, "Comprehensive Organic Transformations", 1989, VCH
• the pyrrolylalkylamines can also be reacted with isocyanates to give the ureas Ih, but instead of the isocyanates it is also possible to use ames HNHR 10 , which are reacted beforehand in a known manner with phosgene or analogous compounds, such as carbonyldiimidazole.
• ames HNHR 10 which are reacted beforehand in a known manner with phosgene or analogous compounds, such as carbonyldiimidazole.
• the compounds according to the invention are antagonists of the excitatory amino acids glutamate, in particular antagonists of the Glycm binding side of the NMDA receptor, the AMPA receptor and the Kamate receptor.
• the pharmacological activity of the compounds I was investigated on isolated membrane material from rat cerebrum.
• the membrane material in the presence of the compounds according to the invention with the radioactively labeled substances
• 3H-2-Am ⁇ no-3-hydroxy-5-methyl-4-isoxazolepropionic acid ( 3 H-AMPA), [ 3 H] -glycine or [ 3 H] -cainates treated, these being specific receptors (AMPA, NMDA - or Kainate receptors) bind.
• AMPA specific receptors
• NMDA NMDA - or Kainate receptors
• a buffer solution A consisting of 30 mM ⁇ , ⁇ , ⁇ -tris (hydroxymethyl) methylamine hydrochloride (TRIS-HCl) and 0.5 mM ethylenediaminetetraacetic acid (EDTA) - pH 7.4 - homogenized using an Ultra-Turrax ® stirrer.
• the suspension was centrifuged at 48,000 g for 20 min. After separation of the supernatant liquid, the proteinaceous membrane material contained in the sediment was washed three times by suspending it in buffer solution A and then centrifuging at 48,000 g for 20 minutes each. The membrane material was then suspended in a 15-fold volume of buffer solution A and incubated at 37 ° C. for 30 min. The protein material was then washed twice by centrifugation and suspension and frozen at -70 ° C until used.
• the protein material thawed at 37 ° C was centrifuged twice at 48,000 g (20 min) and then suspended in a buffer solution B of 50 mM TRIS-HCl, 0.1 M potassium thiocyanate and 2.5 mM calcium chloride - pH 7 , 1 - washed. Then 0.25 mg of membrane material, 0.1 ⁇ Ci 3 H-AMPA (60 Ci / mmol) and compound I were dissolved in 1 ml of buffer solution B and incubated on ice for 60 min. The incubated solution was filtered through a CF / B filter (Whatman), which had previously been treated with a 0.5% aqueous solution of polyethyleneimine for at least 2 hours. The membrane residue was then washed with 5 ml of cold buffer solution B to remove bound and free
• rat hippocampi were homogenized in a 10-fold volume of preparation buffer (50 mM Tris-HCl, 10 mM EDTA) using a Potter homogenizer. The homogenate was centrifuged at 48,000 xg for 20 min. The supernatant was discarded and the membranes obtained in the pellet were washed twice by resuspending and centrifuging at 48000 xg (20 min each). The resuspended membranes were frozen in liquid nitrogen and thawed again at 37 ° C. After a further washing step, the membrane suspension was incubated in a shaking water bath at 37 ° C. for 15 min. After 4 further washing steps (in each case 20 min centrifugation at 48000 xg and resuspending in preparation buffer), the membranes were frozen at -70 ° C. until further use.
• preparation buffer 50 mM Tris-HCl, 10 mM EDTA
• the frozen membranes were thawed at 37 ° C and washed twice by centrifugation at 48000 xg (20 min) and then resuspending in binding buffer (50 mM Tris-HCl pH 7.4; 10 mM MgCl;).
• An incubation batch contained 0.25 mg protein (membranes), 25 nM 3 H-Glycm (16 Ci / mmol) and the substances to be tested in a total of 0.5 ml binding buffer. Non-specific binding was determined by adding 1 mM glycine. After incubation at 4 ° C. for 60 min, bound and free ligand were separated from one another by filtration through GF / B filters and subsequent washing with about 5 ml of ice-cold binding buffer. The radioactivity remaining on the filters is determined by liquid scintillation payment.
• the dissociation constants were calculated from the displacement curves with the aid of an iterative nonlinear adaptation program or according to the equation by Cheng and Prusoff.
• the frozen membranes were thawed at 37 ° C, suspended in binding buffer (50 mM Tris-HCl pH 7.4) and centrifuged at 48,000 x g for 20 min.
• the membranes in the pellet were resuspended in binding buffer.
• An incubation batch contained 0.25 mg protein (membranes), 0.058 ⁇ Ci (58 Ci / mmol) as well as the substances to be tested in a total of 1 ml binding buffer. Non-specific binding was determined in the presence of 0.1 mM glutamate.
• bound and free ligand was separated from one another by filtration through CF / B filters and subsequent washing with 5 ml of ice-cold binding buffer.
• the CF / B filters had previously been treated with 0.5% polyethyleneimine for at least 2 hours.
• the displacement curves were evaluated and the dissociation constants calculated using a non-linear adaptation program or according to the equation by Cheng and Prusoff.
• the compounds I according to the invention are suitable as medicaments for human and veterinary medicine and can be used for the production of medicaments for the treatment of neurodegenerative diseases and neurotoxic disorders of the central nervous system and for the preparation of antiepileptics, anxiolytics and antidepressants.
• the pharmaceutical preparations according to the invention contain a therapeutically effective amount of the compounds I.
• the active ingredients can be contained in the usual concentrations.
• the active ingredients are present in an amount of 0.0001 to 1% by weight, preferably 0.001 to 0.1% by weight.
• the preparations are administered in single doses. 0.1 to 100 mg per kg body weight are given in a single dose.
• the preparations can be administered daily in one or more doses depending on the type and severity of the diseases.
• the pharmaceutical preparations according to the invention contain, in addition to the active ingredient, the customary excipients and diluents.
• pharmaceutical-technical auxiliaries such as ethanol, isopropanol, oxethylated Example 15:
• Example 13 3.4 g (8.3 mmol) of the substance of Example 13 was reduced analogously to Example 12 with 2.8 g (49.9 mmol) of iron powder. Yield: 2.3 g (75%), mp> 200 ° C.
• Example 14 3.6 g (8.8 mmol) of the substance of Example 14 were reduced analogously to Example 12 with 3 g (53 mmol) of iron powder. Yield: 2.9 g
• Example 15 2.7 g (6.4 mmol) of the substance of Example 15 were reduced analogously to Example 12 with 2.1 g (38.2 mmol) of iron powder. Yield: 2.3 g (92%), mp> 250 ° C.
• Example 11 1.4 g (3.8 mmol) of the substance of Example 11 and 0.51 g (38.4 mmol) of 2,5-dimethoxytetrahydrofuran were reacted analogously to Example 17. Yield: 1.1 g (70%), mp> 250 ° C.
• Example 34 1- (2-Methylbenzamido) -7- (3-trifluoroacetamidomethyl-1-pyrrolyl) -6-trifluoromethyl-quinoxaline-2,3- (1H, 4H) -dione
• Example 36 N- (1- (1- (2-Methylbenzamido) -6-trifluoromethyl-quinoxaline-2,3- (1H, 4H) -7-yl) -pyrrol-3-yl) -methyl-N'- phenylurea
• Example 38 7- (3- (4-Benzylpiperazin-1-yl-methyl) -pyrrol-1-yl) -1- (2-methylbenzamido) -6-trifluoromethyl-quinoxaline-2,3- (1H, 4H) -dion
• Example 61 1.0 g (1.8 mmol) of the product from Example 61 were hydrolyzed with lithium hydroxide as in Example 55. 0.7 g (74%) of the product was obtained.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Pain & Pain Management (AREA)
• Psychiatry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=6521350

Family Applications (1)

Country Status (19)

Families Citing this family (5)

Family Cites Families (12)

• 1994
  • 1994-08-09 DE DE4428152A patent/DE4428152A1/de not_active Withdrawn
• 1995
  • 1995-06-15 IL IL11416195A patent/IL114161A0/xx unknown
  • 1995-06-15 HR HRP4428152.8A patent/HRP950339A2/xx not_active Application Discontinuation
  • 1995-06-16 AU AU28835/95A patent/AU2883595A/en not_active Abandoned
  • 1995-06-16 SI SI9520076A patent/SI9520076A/sl unknown
  • 1995-06-16 EP EP95924247A patent/EP0873321A1/de not_active Withdrawn
  • 1995-06-16 PL PL95317967A patent/PL317967A1/xx unknown
  • 1995-06-16 HU HU9603544A patent/HUT76472A/hu unknown
  • 1995-06-16 CA CA002193732A patent/CA2193732A1/en not_active Abandoned
  • 1995-06-16 MX MX9700113A patent/MX9700113A/es unknown
  • 1995-06-16 WO PCT/EP1995/002324 patent/WO1995035289A1/de not_active Application Discontinuation
  • 1995-06-16 CN CN95194177A patent/CN1152918A/zh active Pending
  • 1995-06-16 US US08/765,260 patent/US5773439A/en not_active Expired - Fee Related
  • 1995-06-16 BR BR9508112A patent/BR9508112A/pt not_active Application Discontinuation
  • 1995-06-16 JP JP8501651A patent/JPH10501801A/ja not_active Abandoned
  • 1995-06-21 ZA ZA955128A patent/ZA955128B/xx unknown
• 1996
  • 1996-12-20 FI FI965172A patent/FI965172A/fi unknown
  • 1996-12-23 NO NO965553A patent/NO965553L/no unknown
• 1997
  • 1997-01-06 BG BG101114A patent/BG101114A/xx unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events